Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease
2022
Xue Guo | Xue Guo | Chen Huang | Jing Xu | Jing Xu | Haoming Xu | Le Liu | Hailan Zhao | Hailan Zhao | Jiaqi Wang | Jiaqi Wang | Wenqi Huang | Wenqi Huang | Wu Peng | Wu Peng | Ye Chen | Yuqiang Nie | Yuqiang Nie | Yongjian Zhou | Yongjian Zhou | Youlian Zhou | Youlian Zhou
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterized by relapse and remission alternately. It remains a great challenge to diagnose and assess disease activity during IBD due to the lack of specific markers. While traditional biomarkers from plasma and stool, such as C-reactive protein (CRP), fecal calprotectin (FC), and S100A12, can be used to measure inflammation, they are not specific to IBD and difficult to determine an effective cut-off value. There is consensus that gut microbiota is crucial for intestinal dysbiosis is closely associated with IBD etiopathology and pathogenesis. Multiple studies have documented differences in the composition of gut microbiota between patients with IBD and healthy individuals, particularly regarding microbial diversity and relative abundance of specific bacteria. Patients with IBD have higher levels of Proteobacteria and lower amounts of Bacteroides, Eubacterium, and Faecalibacterium than healthy individuals. This review summarizes the pros and cons of using traditional and microbiota biomarkers to assess disease severity and treatment outcomes and addresses the possibility of using microbiota-focused interventions during IBD treatment. Understanding the role of microbial biomarkers in the assessment of disease activity and treatment outcomes has the potential to change clinical practice and lead to the development of more personalized therapies.
显示更多 [+] 显示较少 [-]